ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).
 PMID: 19566959       2009       Journal of the International AIDS Society
Abstract: The main differences are reflected in the discoveries that: (i) the non-nucleoside reverse transcriptase inhibitor resistance mutation, V106M, has been seen in subtype C and CRF01_AE, but not in subtype B, (ii) the protease inhibitor mutations L89I/V have been reported in C, F and G subtypes, but not in B, (iii) a nelfinavir selected non-D30N containing pathway predominated in CRF01_AE and CRF02_AG, while the emergence of D30N is favoured in subtypes B and D, (iv) studies on thymidine analog-treated subtype C infections from South Africa, Botswana and Malawi have reported a higher frequency of the K65R resistance mutation than that typically seen with subtype B.Additionally, some substitutions that seem to impact non-B viruses differentially a


  Darunavir: a review of its use in the management of HIV infection in adults.
 PMID: 19323590       2009       Drugs
Abstract: In a 24-week analysis of pooled data from the POWER 1 and 2 studies in treatment-experienced patients, 11 protease mutations associated with a reduced response to boosted darunavir were identified (V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V and L89V).


  Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
 PMID: 18039922       2008       Antimicrobial agents and chemotherapy
Abstract: The most common mutations that emerged at rebound included V32I (44%), I54M/L (24%), L33F (25%), I84V (21%), and L89V (12%).


  Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.
 PMID: 18625773       2008       Antimicrobial agents and chemotherapy
Abstract: Mutations at six residues were associated with a lower VR (E35D/G/K/N, M36I/L/V, Q58E, Q61D/E/G/H/N/R, H69I/K/N/Q/R/Y, and L89I/M/R/T/V), and one mutation was associated with a higher VR (F53L/W/Y).
Abstract: The genotypic score M36I/L/V-53L/W/Y + Q58E + H69I/K/N/Q/R/Y + L89I/M/R/T/V was selected as providing a strong association with VR.


  Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.
 PMID: 18690163       2008       AIDS (London, England)
Abstract: Emergence of DRV-associated-resistance mutations was observed in 72% (18/25) of patients, at codons L89I/M/V (32%), V32I (28%), V11I (20%), I47V/A (20%), I54L/M (20%), L33F/I (16%) and I50V (16%).


  Combating HIV resistance - focus on darunavir.
 PMID: 19209258       2008       Therapeutics and clinical risk management
Abstract: Darunavir resistance-associated mutations have been defined as V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V, and L89V.


  Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
 PMID: 17646201       2007       The Journal of antimicrobial chemotherapy
Abstract: For minor darunavir resistance mutations, the rates were V11I 3.3%, V32I 3.9%, L33F 11%, I47V 2.1%, I54L 2.3%, G73S 12.8% and L89V 2.4%.



Browser Board

 Co-occurred Entities




   Filtrator